Biohaven Pharmaceutical Holding Company Ltd. BHVN 深 滬
等待開盤 09-20 09:30:00 美东时间
40.42
+1.020
+2.59%
華盛通- 最 高41.54
- 今 開40.70
- 成交量 109.47万股
- 最 低 39.8592
- 昨 收 39.40
- 總市值 32.97亿
- 52周最高 62.21
- 市盈率 靜 --
- 換手率 1.34%
- 52周最低 16.48
- 委 比 0.00%
- 總股本 8157.99万
- 歷史最高 152.56
- 量 比 1.14
- 振 幅 4.27%
- 歷史最低 7.10
- 每 手 1
- 風險率 9.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BofA starts Biohaven at buy, cites "fast-follower" approach
BofA started coverage of Biohaven (NYSE:BHVN) with a buy rating, citing its drug development programs for mood and autoimmune disorders. The investment bank said it liked Biohaven’s “’fast-follower’ a...
08-27 02:11
Biohaven Non-GAAP EPS of -$3.50 misses by $1.80
Biohaven press release (NYSE:BHVN): Q2 Non-GAAP EPS of -$3.50 misses by $1.80. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024. Mo...
08-09 15:26
Biohaven Q2 Adj $(3.50) Misses $(1.77) Estimate
Biohaven (NYSE:BHVN) reported quarterly losses of $(3.50) per share which missed the analyst consensus estimate of $(1.77) by 97.74 percent. This is a 180 percent decrease over losses of $(1.25) per share from the same
08-09 05:51
Biohaven Insider Buyers See Boost After Market Cap Rose US$317m
Insiders who bought Biohaven Ltd. (NYSE:BHVN) stock in the last 12 months were ...
07-16 01:09
RBC Capital Remains a Buy on Biohaven Ltd. (BHVN)
In a report released today, Leonid Timashev from RBC Capital maintained a Buy r...
06-17 18:41
HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.
05-31 02:47
Cantor Fitzgerald Reiterates Overweight on Biohaven
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
05-30 23:39
Goldman Sachs raises obesity drug market estimate to $130B
Weight loss drugmakers Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) traded higher on Thursday as Goldman Sachs projected global sales from next-gen obesity drugs could reach $130B in 2030, up from its ...
05-30 23:22
